{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-Polycythemia+Vera+Myelofibrosis+%28Post-PV+MF%29&page=2", "query": { "condition": "Post-Polycythemia Vera Myelofibrosis (Post-PV MF)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-Polycythemia+Vera+Myelofibrosis+%28Post-PV+MF%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T04:05:50.372Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05280509", "title": "Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post-PV MF", "Post-ET Myelofibrosis" ], "interventions": [ { "name": "TL-895", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telios Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2022-06-09", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Canton, Ohio • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05280509" }, { "nct_id": "NCT02718300", "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2017-02-08", "completion_date": "2022-04-29", "has_results": true, "last_update_posted_date": "2024-05-01", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718300" }, { "nct_id": "NCT02098161", "title": "LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Smac Mimetic LCL161", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-12-18", "completion_date": "2022-05-19", "has_results": true, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098161" }, { "nct_id": "NCT03662126", "title": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Primary Myelofibrosis (PMF)", "Post-Polycythemia Vera MF (Post-PV-MF)", "Post-Essential Thrombocythemia MF (Post-ET-MF)" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" }, { "name": "Best Available Therapy (BAT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2019-01-15", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03662126" }, { "nct_id": "NCT01773187", "title": "Pacritinib Versus Best Available Therapy to Treat Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Best Available Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 327, "start_date": "2013-01", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2020-09-29", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Morristown, New Jersey + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773187" }, { "nct_id": "NCT04629508", "title": "To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Polycythemia Vera", "Thrombocythemia" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-07-12", "completion_date": "2023-08-24", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 8, "location_summary": "New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Brick", "state": "New Jersey" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629508" }, { "nct_id": "NCT04485260", "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2021-01-28", "completion_date": "2024-10", "has_results": false, "last_update_posted_date": "2022-05-09", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 8, "location_summary": "Duarte, California • Baltimore, Maryland • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04485260" }, { "nct_id": "NCT04854096", "title": "Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis", "Post-polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "NS-018", "type": "DRUG" }, { "name": "Best Available Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NS Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-01-31", "completion_date": "2024-05-16", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 3, "location_summary": "Worcester, Massachusetts • Houston, Texas", "locations": [ { "city": "Worcester", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04854096" }, { "nct_id": "NCT06343805", "title": "A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "PMF", "PPV-MF", "PET-MF" ], "interventions": [ { "name": "AJ1-11095", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ajax Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2024-10-23", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 13, "location_summary": "Palo Alto, California • Tampa, Florida • Kansas City, Kansas + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06343805" }, { "nct_id": "NCT02124746", "title": "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis", "Polycythemia Vera", "Essential Thrombocythemia" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2014-04-30", "completion_date": "2018-12-06", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-05-22T04:05:50.372Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Orange, California • Stanford, California + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02124746" } ] }